Patent classifications
G01N33/537
METHOD OF FABRICATING SUBSTRATE FOR ANALYSIS, SUBSTRATE FOR ANALYSIS, AND ANALYSIS UNIT
A method of fabricating a substrate for analysis fixes antibodies that specifically react with specific antigens included in detection target substances to the substrate for analysis. The method subjects the substrate for analysis to immersion treatment with a predetermined treatment solution so as to form antibody aggregations in which the antibodies are aggregated at boundary regions between recesses and convex portions on the substrate for analysis. The method causes the antigens and the antibodies to react with each other so as to capture the detection target substances on the substrate for analysis by the antibody aggregations.
METHOD OF FABRICATING SUBSTRATE FOR ANALYSIS, SUBSTRATE FOR ANALYSIS, AND ANALYSIS UNIT
A method of fabricating a substrate for analysis fixes antibodies that specifically react with specific antigens included in detection target substances to the substrate for analysis. The method subjects the substrate for analysis to immersion treatment with a predetermined treatment solution so as to form antibody aggregations in which the antibodies are aggregated at boundary regions between recesses and convex portions on the substrate for analysis. The method causes the antigens and the antibodies to react with each other so as to capture the detection target substances on the substrate for analysis by the antibody aggregations.
METHOD FOR DETECTION OF CELLS BY REPETITIVE STAINING AND DESTAINING
The invention is directed to a method for detecting a target moiety in a sample of biological specimens by providing a conjugate with the general formula (I)
##STR00001## characterized in contacting the sample of biological specimens with at least one conjugate (I), thereby labeling the target moiety recognized by an antigen recognizing moiety with the conjugate (I); exciting the labelled target moieties with light having a wavelength within the absorbance spectrum of the fluorescent moiety FL; detecting the labelled target moieties by detecting the fluorescence radiation emitted by the fluorescent moiety FL and degrading the fluorescent moiety FL of the labelled target moieties by irradiating the conjugate with light having a wavelength within the absorbance spectrum of fluorescent moiety FL for a time sufficient to deliver enough energy to reduce the fluorescence radiation emitted by the fluorescent moiety FL at least by 75% of the initial fluorescence radiation.
METHOD FOR DETECTION OF CELLS BY REPETITIVE STAINING AND DESTAINING
The invention is directed to a method for detecting a target moiety in a sample of biological specimens by providing a conjugate with the general formula (I)
##STR00001## characterized in contacting the sample of biological specimens with at least one conjugate (I), thereby labeling the target moiety recognized by an antigen recognizing moiety with the conjugate (I); exciting the labelled target moieties with light having a wavelength within the absorbance spectrum of the fluorescent moiety FL; detecting the labelled target moieties by detecting the fluorescence radiation emitted by the fluorescent moiety FL and degrading the fluorescent moiety FL of the labelled target moieties by irradiating the conjugate with light having a wavelength within the absorbance spectrum of fluorescent moiety FL for a time sufficient to deliver enough energy to reduce the fluorescence radiation emitted by the fluorescent moiety FL at least by 75% of the initial fluorescence radiation.
ASSESSMENT OF PREECLAMPSIA USING ASSAYS FOR FREE AND DISSOCIATED PLACENTAL GROWTH FACTOR
Described herein are methods, compositions, kits, and systems for detecting free and bound PlGF, and using detection of such species to distinguish between pregnant women with or without preeclampsia or related conditions.
Methods for Categorizing and Treating Subjects at Risk for Pulmonary Exacerbation and Disease Progression
The present invention is related to novel methods for categorizing and treating a population of subjects that are at risk for increased pulmonary exacerbation and disease progression.
Methods for Categorizing and Treating Subjects at Risk for Pulmonary Exacerbation and Disease Progression
The present invention is related to novel methods for categorizing and treating a population of subjects that are at risk for increased pulmonary exacerbation and disease progression.
Parallel Flow Cytometer Using Radiofrequency Multiplexing
An imaging flow cytometry apparatus and method which allows registering multiple locations across a cell, and/or across multiple flow channels, in parallel using radio-frequency-tagged emission (FIRE) coupled with a parallel optical detection scheme toward increasing analysis throughput. An optical source is modulated by multiple RF frequencies to produce an optical interrogation beam having a spatially distributed beat frequency. This beam is directed to one or more focused streams of cells whose responsive fluorescence, in different frequencies, is registered in parallel by an optical detector.
Parallel Flow Cytometer Using Radiofrequency Multiplexing
An imaging flow cytometry apparatus and method which allows registering multiple locations across a cell, and/or across multiple flow channels, in parallel using radio-frequency-tagged emission (FIRE) coupled with a parallel optical detection scheme toward increasing analysis throughput. An optical source is modulated by multiple RF frequencies to produce an optical interrogation beam having a spatially distributed beat frequency. This beam is directed to one or more focused streams of cells whose responsive fluorescence, in different frequencies, is registered in parallel by an optical detector.
Method for the determination of anti-drug antibodies against an effector function suppressed human or humanized drug antibody
Herein is reported an anti-drug antibody immunoassay for the determination of the presence of an anti-drug antibody against an effector function suppressed human or humanized drug antibody in a sample comprising the incubation of a sample comprising mammalian blood serum with full length human Fcgamma receptor I or an Fc-region binding fragment thereof so that a complex between the anti-drug antibody against the effector function suppressed human or humanized drug antibody present in the sample and the human Fcgamma receptor I or the Fc-region binding fragment thereof forms, whereby the full length human Fcgamma receptor I or the Fc-region binding fragment thereof is conjugated to a detectable label, and the determination of the formed complex by the detectable label.